Sleep and orexin : A new paradigm for understanding behavioural-variant frontotemporal dementia?
Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved..
Behavioural variant frontotemporal dementia (bvFTD) is a complex and heterogeneous disorder with as yet unidentified unifying pathophysiological mechanism. There is emerging evidence that hypothalamic dysfunction, manifesting as disturbances in sleep and metabolism, is an integral component of neurodegeneration in bvFTD. Although sleep and metabolic disturbances and the behavioural abnormalities of bvFTD may appear disparate on the surface, there may be a common underlying hormonal mechanism involving orexin. Orexin is a hypothalamic neurotransmitter directly responsible for control of sleep and metabolism in healthy individuals and is implicated in many abnormal behaviours commonly seen in bvFTD - such as impulsive behaviour, hedonistic reinforcement and binge-consumption of ethanol. Further characterising orexin's role in pathophysiology of bvFTD could lead to a new paradigm for understanding this disease and may provide a new direction towards effective management and treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Sleep medicine reviews - 54(2020) vom: 05. Dez., Seite 101361 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hwang, Yun Tae [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Behavioural-variant frontotemporal dementia |
|---|
| Anmerkungen: |
Date Completed 04.10.2021 Date Revised 04.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.smrv.2020.101361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313212791 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313212791 | ||
| 003 | DE-627 | ||
| 005 | 20231225150107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.smrv.2020.101361 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313212791 | ||
| 035 | |a (NLM)32745956 | ||
| 035 | |a (PII)S1087-0792(20)30104-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hwang, Yun Tae |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sleep and orexin |b A new paradigm for understanding behavioural-variant frontotemporal dementia? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2021 | ||
| 500 | |a Date Revised 04.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a Behavioural variant frontotemporal dementia (bvFTD) is a complex and heterogeneous disorder with as yet unidentified unifying pathophysiological mechanism. There is emerging evidence that hypothalamic dysfunction, manifesting as disturbances in sleep and metabolism, is an integral component of neurodegeneration in bvFTD. Although sleep and metabolic disturbances and the behavioural abnormalities of bvFTD may appear disparate on the surface, there may be a common underlying hormonal mechanism involving orexin. Orexin is a hypothalamic neurotransmitter directly responsible for control of sleep and metabolism in healthy individuals and is implicated in many abnormal behaviours commonly seen in bvFTD - such as impulsive behaviour, hedonistic reinforcement and binge-consumption of ethanol. Further characterising orexin's role in pathophysiology of bvFTD could lead to a new paradigm for understanding this disease and may provide a new direction towards effective management and treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Behavioural-variant frontotemporal dementia | |
| 650 | 4 | |a Pathophysiology | |
| 650 | 4 | |a Sleep | |
| 650 | 4 | |a orexin | |
| 650 | 7 | |a Orexins |2 NLM | |
| 700 | 1 | |a Piguet, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Hodges, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Grunstein, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Burrell, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Sleep medicine reviews |d 1997 |g 54(2020) vom: 05. Dez., Seite 101361 |w (DE-627)NLM097427322 |x 1532-2955 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2020 |g day:05 |g month:12 |g pages:101361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.smrv.2020.101361 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2020 |b 05 |c 12 |h 101361 | ||